Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | CTSC | P53634 | 2/20 | 0.51 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.50 |
| ▸ | INSR | P06213 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | CCNK | O75909 | 2/20 | 0.48 |
| ▸ | CCND3 | P30281 | 2/20 | 0.48 |
| ▸ | CDK9 | P50750 | 2/20 | 0.48 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833021 | 1.00 | EGFR (0.51) | EGFRCTSCALKINSRIGF1R | |
| SCHEMBL24620223 | 0.89 | ALK (0.56) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL30833033 | 0.89 | ALK (0.56) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL29791364 | 0.87 | ALK (0.67) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL24620284 | 0.87 | ALK (0.67) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL24620272 | 0.85 | ALK (0.61) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL29791447 | 0.85 | ALK (0.61) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL24620279 | 0.85 | ALK (0.59) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL29791371 | 0.85 | ALK (0.59) | EGFRALKINSRIGF1RMAP3K7 | |
| SCHEMBL24620250 | 0.85 | CCNK (0.66) | EGFRCTSCALKMAP3K7SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | claimed |
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | SINAI HEALTH SYSTEM (CA) | 2024-03-21 | — | — | US | disclosed |
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092763-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | NUAK1, NUAK2, NEK1 | EGFR 1022/4885CTSC 2091/4885ALK 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.